Clinical Training Update: ISIS-GCGRRx - Dose Level 1, ISIS-GCGRRx - Dose Level 2, Placebo
=========================================================================================

TO: All Clinical Staff
FROM: Medical Education Department
DATE: September 14, 2025
SUBJECT: Important Clinical Update - ISIS-GCGRRx - Dose Level 1, ISIS-GCGRRx - Dose Level 2, Placebo

BACKGROUND:
This memo provides important updates regarding ISIS-GCGRRx - Dose Level 1, ISIS-GCGRRx - Dose Level 2, Placebo that affect current
clinical protocols and patient care procedures.

CURRENT PROTOCOLS:
• Current dosing guidelines: Study protocol dosing
• Monitoring requirements: Standard study precautions
• Indications for use: Investigational use

CLINICAL CONSIDERATIONS:
Staff should be aware that current protocols for ISIS-GCGRRx - Dose Level 1, ISIS-GCGRRx - Dose Level 2, Placebo are based on
Standard study precautions. 

Patient population affected: Clinical trial participants (n=77)
Risk level: Medium
Contraindications: Per trial protocol

ADVERSE EVENTS TO MONITOR:
As reported in trial monitoring

MECHANISM OF ACTION:
Under clinical investigation

THERAPEUTIC CLASS:
Clinical Trial

COMPLIANCE REQUIREMENTS:
All staff must review and acknowledge this update by 2025-12-13.

QUESTIONS:
Contact the Medical Education Department with any questions or concerns
regarding these clinical updates.

---
Medical Education Department
Internal Distribution Only
Document ID: MED-5081
Revision Date: January 2025
